Phrontline Biopharma (Hangzhou) Co. Ltd. has prepared and tested bispecific antibody-drug conjugates (bsADCs) comprising a bispecific antibody targeting B7 homolog 3 (B7-H3; CD276) and EGFR (HER1; erbB1) linked to a cytotoxic drug. They are described as potentially useful for the treatment of cancer.
Shanghai Allink Biotherapeutics Co. Ltd. has discovered new bispecific antibody-drug conjugates comprising a bispecific monoclonal antibody linked to a cytotoxic drug potentially useful for the treatment of cancer.
Mesothelin (MSLN) is a highly expressed protein in several cancer types but with limited expression in normal tissues. Simcere Pharmaceutical Co. Ltd. has presented preclinical data on the characterization of SCR-A019, an antibody-drug conjugate (ADC) carrying a topoisomerase 1 inhibitor payload and an antibody that binds to membrane Mesothelin (MSLN) over soluble MSLN and has shown robust antitumor efficacy in several cell-derived xenograft models.
Pheast Therapeutics Inc. has presented preclinical data on PHST-677, a novel bispecific antibody-drug conjugate (ADC) targeting E-cadherin (CDH1) and Nectin-4.
Shanghai Ailux Biotechnology Co. Ltd. has patented new antibody-drug conjugates consisting of an antibody targeting fibroblast growth factor receptor 2 isoform 2 (FGFR2; FGFR2b) covalently linked to a cytotoxic drug intended for use in the treatment of cancer.
Researchers from Takeda Pharmaceutical Co. Ltd. detailed the preclinical characterization of TAK-188, a first-in-class anti-CCR8 antibody-drug conjugate (ADC) designed to selectively target CCR8+ Tregs, alleviating immunosuppression in the tumor microenvironment.
Biolojic Design Ltd. has reported preclinical data for its antibody-drug conjugate (ADC) BD-200, developed using an AI-guided antibody engineering platform named Multibody.
Arrivent Biopharma Inc. has obtained IND clearance from the FDA for ARR-002 (AV-P138-ADC), an antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors. A phase I trial is expected to open in the second half of the year.
Biosion Inc. recently presented preclinical data describing their B7H3/PD-L1 bispecific antibody-drug conjugate (ADC) BSI-737 for the treatment of cancer.
Beijing Innocare Pharma Tech Co. Ltd. has received IND approval from China’s National Medical Products Administration (NMPA) for ICP-B208, an antibody-drug conjugate targeting CDH17, which is highly expressed in gastrointestinal cancers, including colorectal, gastric and biliary tract cancers and pancreatic ductal adenocarcinoma.
RSS
